Ligand gains foothold in China with liver disease deal
This article was originally published in Scrip
Ligand Pharmaceuticals has taken an indirect step into China through the granting of licences for this burgeoning market to two clinical-stage programmes and technology acquired as part of its purchase of Metabasis a year ago.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.